Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Circulating levels of oestradiol, follicle-stimulating hormone and luteinizing hormone at baseline and after 12 months, and change from baseline to 12 months by treatment group

From: Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]

  Isoflavone group (n= 56) Placebo (n = 61)a  
  Baseline 12 months Change Baseline 12 months Change P for changeb
Oestradiol (pmol/l) 22.6 ± 12.2 36.6 ± 65.0 14.0 ± 64.7 22.6 ± 13.3 21.6 ± 9.0 -0.9 ± 11.5 0.49
FSH (IU/l) 76.2 ± 21.5 72.0 ± 23.5 -4.2 ± 12.9 77.6 ± 25.1 74.5 ± 23.9 -2.9 ± 13.0 0.83
LH (IU/l) 43.9 ± 15.4 39.9 ± 14.6 -4.0 ± 11.7 45.5 ± 16.0 41.2 ± 12.0 -4.2 ± 9.2 0.71
  1. Values are expressed as means ± standard deviation. aFor change in FSH, n = 60. b P value for difference between treatment groups for change. FSH, follicle-stimulating hormone; LH, luteinizing hormone.